Chemoembolization of hepatocellular carcinoma

Area of Science:

• Hepatobiliary oncology
• Interventional radiology
• Pharmacology

Background:

• Transarterial chemoembolization (TACE) is standard for intermediate hepatocellular carcinoma (HCC).
• Conventional TACE improves median survival from 16 to 20 months but has limitations.
• Drug-eluting beads (DEB) offer improved TACE pharmacokinetics and reduced systemic exposure.

Purpose of the Study:

• To review the technique, indications, and outcomes of conventional and DEB-TACE for HCC.
• To discuss the scientific basis and early clinical experience of combining TACE with antiangiogenic agents.
• To highlight DEB-TACE combined with antiangiogenic therapy as a promising approach.

Main Methods:

• Meta-analysis of randomized controlled trials comparing conventional TACE with best supportive care.
• Review of randomized trials evaluating DEB-TACE versus conventional TACE.
• Discussion of scientific literature and early clinical data on combination therapies.

Main Results:

• Conventional TACE improved median survival in HCC patients.
• DEB-TACE demonstrated improved pharmacokinetic profiles, consistency, and repeatability.
• DEB-TACE significantly reduced liver toxicity and drug-related adverse events compared to conventional TACE.

Conclusions:

• DEB-TACE offers advantages over conventional TACE in managing HCC.
• Combination therapy with DEB-TACE and antiangiogenic agents is under investigation.
• This combination therapy shows potential for improved HCC treatment outcomes.